NCT00797303View on ClinicalTrials.gov

The Effect of Bevacizumab on Corneal Neovascularization

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

November 30, 2008

Conditions
Corneal Neovascularization
Interventions
DRUG

Bevacizumab

subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

All Listed Sponsors
lead

Instituto de Olhos de Goiania

OTHER

NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization | Biotech Hunter | Biotech Hunter